Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0362)
| Name |
1-Methylnaphthalene-4-propionate endoperoxide
|
||||
|---|---|---|---|---|---|
| Synonyms |
1-Methylnaphthalene-4-propionate endoperoxide; SCHEMBL86110; 3-(1,4-epidioxy-4-methyl-1,4-dihydro-1-naphthyl)propionic acid; 3-(8-Methyl-9,10-dioxatricyclo[6.2.2.02,7]dodeca-2,4,6,11-tetraen-1-yl)propanoic acid
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C14H14O4
|
||||
| IUPAC Name |
3-(8-methyl-9,10-dioxatricyclo[6.2.2.02,7]dodeca-2,4,6,11-tetraen-1-yl)propanoic acid
|
||||
| Canonical SMILES |
CC12C=CC(C3=CC=CC=C31)(OO2)CCC(=O)O
|
||||
| InChI |
InChI=1S/C14H14O4/c1-13-8-9-14(18-17-13,7-6-12(15)16)11-5-3-2-4-10(11)13/h2-5,8-9H,6-7H2,1H3,(H,15,16)
|
||||
| InChIKey |
ANJQRGGBEZTGOB-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | Hepa 1-6 cells | Hepatocellular carcinoma | Mus musculus | CVCL_0327 |
| Response regulation | 1-Methylnaphthalene-4-propionate endoperoxide (MNPE) is a cell-permeable endoperoxide that generates pure singlet oxygen. MNPE treatment decreased the viabilities of mouse liver cancer cells in vitro, and that this decrease was accompanied by increases in the concentrations of both intracellular ferrous iron and the level of lipid peroxidation. | |||